Xiantong Pharmaceutical-B (09941) Opens Subscription from November 16 to November 19, Plans Global Offering of 6.561 Million H Shares

Stock News11-16

Xiantong Pharmaceutical-B (09941) will take subscriptions from November 16 to November 19, 2026, offering 6.561 million H shares globally, with 10% allocated to Hong Kong and 90% to international placements, at a price range of HK$52.0 to HK$68.0 per share, with each board lot comprising 50 shares, and the shares are expected to commence trading on the Stock Exchange on November 24, 2026.

The company is dedicated to the development and commercialization of diagnostic and therapeutic radiopharmaceuticals with substantial market potential. Founded in 2005, as of the latest practicable date, the company has established a phased, indication-oriented development pipeline comprising 13 assets, of which 5 were independently discovered and developed in-house and 3 were independently developed by the company. The company's pipeline includes two core products, XTR008 and XTR004, as well as two major products, XTR003 and XTR006.

XTR008 is a registration-stage 177Lu-labeled radiopharmaceutical targeting somatostatin receptor (SSTR) for the treatment of neuroendocrine neoplasms (NEN). It is a generic version of Lutathera® and is the first in its class to submit an NDA to the National Medical Products Administration as a Class 3 chemical drug, with marketing approval expected in December 2026.

For the years ended December 31, 2024 and 2025, and for the six months ended June 30, 2025 and 2026, the company recorded revenue of RMB 44.1 million, RMB 99.2 million, RMB 36.9 million, and RMB 61.3 million, respectively. For the years ended December 31, 2024 and 2025, and for the six months ended June 30, 2025 and 2026, the company recorded net losses of RMB 156 million, RMB 618 million, RMB 328 million, and RMB 534 million, respectively.

Assuming the over-allotment option is not exercised and the offer price is HK$60.0 per share (being the mid-point of the indicative offer price range stated in the prospectus), after deducting underwriting commissions, fees, and other estimated expenses paid and payable in connection with the global offering, the company estimates that the net proceeds from the global offering will be approximately HK$329 million. If the offer price is set at HK$52.0 per share (being the lower limit of the indicative offer price range), the net proceeds from the global offering will decrease by approximately HK$50.4 million. If the offer price is set at HK$68.0 per share (being the upper limit of the indicative offer price range), the net proceeds from the global offering will increase by approximately HK$50.4 million.

Assuming the offer price is set at the mid-point of the indicative offer price range and the over-allotment option is not exercised, the company intends to apply the net proceeds from the global offering as follows: 88.0% for research and development and registration filings of core products; 4.9% for research and development of the company's other candidate products; 1.1% for strengthening the company's sales and marketing capabilities; 1.1% for constructing a new production base in Tianjin; and 5.0% as working capital and other general corporate purposes.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment